Gastrointestinal Stromal Tumor Market Report 2026
Global Outlook – By Treatment Type (Chemotherapy, Targeted Therapy, Other Treatment Types), By Indication (Stomach, Small Intestine, Others Indications), By End-User (Hospitals, Clinics, Specialized Cancer Treatment Centers, Other End-Users) - Market Size, Trends, Strategies, and Forecast to 2030
Gastrointestinal Stromal Tumor Market Overview
• Gastrointestinal Stromal Tumor market size has reached to $1.36 billion in 2025 • Expected to grow to $1.98 billion in 2030 at a compound annual growth rate (CAGR) of 8% • Growth Driver: Growing Incidence Of Stomach Cancer To Boost The Market • Market Trend: Clinical Advancements Reinforce The Expansion Of Targeted Therapies For GIST Patients • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.What Is Covered Under Gastrointestinal Stromal Tumor Market?
A gastrointestinal stromal tumor (GIST) is a type of rare, non-epithelial tumor that originates in the gastrointestinal (GI) tract. These are most commonly developed in the stomach or the small intestine, but they can occur anywhere along the GI tract, from the esophagus to the rectum. The main treatment types of gastrointestinal stromal tumors are chemotherapy, targeted therapy, and others. Chemotherapy is a medical treatment that uses powerful drugs to target and kill rapidly dividing cells in the body, including cancer cells. It is indicated for various indications such as stomach, small intestine, and others, by different end-users including hospitals, clinics, specialized cancer treatment centers, and others.
What Is The Gastrointestinal Stromal Tumor Market Size and Share 2026?
The gastrointestinal stromal tumor market size has grown strongly in recent years. It will grow from $1.36 billion in 2025 to $1.46 billion in 2026 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to approval of imatinib therapy, improved tumor classification, expansion of oncology care centers, increased awareness of rare gi tumors, availability of surgical interventions.What Is The Gastrointestinal Stromal Tumor Market Growth Forecast?
The gastrointestinal stromal tumor market size is expected to see strong growth in the next few years. It will grow to $1.98 billion in 2030 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to development of next-generation targeted therapies, growth in precision diagnostics, increased clinical trials, expansion of personalized cancer treatment, improved survival outcomes. Major trends in the forecast period include rising use of targeted tyrosine kinase inhibitors, increased focus on molecular tumor profiling, expansion of precision oncology approaches, growth in surgical and drug combination therapy, improved long-term disease management.
Global Gastrointestinal Stromal Tumor Market Segmentation
1) By Treatment Type: Chemotherapy, Targeted Therapy, Other Treatment Types 2) By Indication: Stomach, Small Intestine, Others Indications 3) By End-User: Hospitals, Clinics, Specialized Cancer Treatment Centers, Other End-Users Subsegments: 1) By Chemotherapy: Traditional Chemotherapy Agents, Combination Chemotherapy Regimens 2) By Targeted Therapy: Tyrosine Kinase Inhibitors, Other Targeted Agents 3) By Other Treatment Types: Surgery, Radiation Therapy, Clinical Trials For Novel TherapiesWhat Is The Driver Of The Gastrointestinal Stromal Tumor Market?
The growing incidence of stomach cancer is expected to propel the growth of the gastrointestinal stromal tumor market going forward. Stomach cancer refers to the uncontrolled growth and multiplication of malignant cells in the lining of the stomach. while gastrointestinal stromal tumors (GISTs) can occur in the stomach, they are distinct from stomach cancer. When two separate tumors collide and merge into one, patients with GISTs have been found to have an increased risk of developing additional cancers, including small bowel adenocarcinoma. For instance, in January 2024, according to the American Cancer Society, a US-based professional organization, around 26,890 new cases of stomach cancer and 10,880 deaths are anticipated in the U.S. for 2024, accounting for 1.5% of all new cancer diagnoses. Therefore, the growing incidence of stomach cancer is driving the growth of the gastrointestinal stromal tumor industry.Key Players In The Global Gastrointestinal Stromal Tumor Market
Major companies operating in the gastrointestinal stromal tumor market are Pfizer Inc., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Merck & Co. Inc., GlaxoSmithKline plc, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca plc, Eli Lilly and Company, Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Jiangsu Hengrui Medicine Co. Ltd., Exelixis Inc., NATCO Pharma Ltd., Blueprint Medicines Corporation, Array BioPharma Inc., Deciphera Pharmaceuticals Inc., Ono Pharmaceutical Co. Ltd.
This chart is for illustrative purposes; the full report includes a detailed competitor analysis and comprehensive overview of the top 10 companies in the market.
This chart maps companies by product innovation and brand strength, with bubble size indicating relative revenue, helping identify market leaders, challengers, and niche players. This is an illustrative chart; the full report provides a complete and accurate competitive analysis.
Explore how leading companies compare across key metrics in our report Get Report
Global Gastrointestinal Stromal Tumor Market Trends and Insights
Major companies operating in the gastrointestinal stromal tumor market are innovating new drugs such as signal transduction and targeted therapy to improve treatment efficacy, address resistance to existing therapies, and meet unmet clinical needs. Signal transduction and targeted therapy refer to treatments designed to block or modify specific cellular signaling pathways that drive tumor growth and survival. For instance, in November 2025, Ascentage Pharma Group International Inc., a China-based commercial-stage biopharmaceutical company, announced the publication of Phase Ib clinical data for olverembatinib (HQP1351) in Signal Transduction and Targeted Therapy, highlighting promising efficacy and safety in SDH-deficient gastrointestinal stromal tumors (GIST) and identifying a new antitumor mechanism involving lipid metabolism modulation.What Are Latest Mergers And Acquisitions In The Gastrointestinal Stromal Tumor Market?
In February 2025, GSK plc, a U.K.-based global biopharmaceutical company providing prescription medicines, vaccines, and specialty treatments, acquired IDRx, Inc. for an undisclosed amount. With this acquisition, GSK aims to strengthen its precision oncology portfolio and expand its pipeline of targeted therapies for gastrointestinal stromal tumors. IDRx, Inc. is a U.S.-based clinical-stage biotechnology company developing precision therapies for rare cancers, with a focus on molecularly driven GIST treatments, including its lead KIT tyrosine kinase inhibitor, IDRX 42.
Regional Outlook
North America was the largest region in the gastrointestinal stromal tumor market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.Need data for a specific geography? Request Regional Data
What Defines the Gastrointestinal Stromal Tumor Market?
The gastrointestinal stromal tumor market includes revenues earned by entities by providing services such as diagnostic services, pathology services, pathology services, and pathology services. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastrointestinal stromal tumor market also includes sales of targeted therapy, chemotherapy, radiation therapy. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This chart presents market attractiveness based on a quantitative evaluation of growth, competition, strategic alignment, and risk, offering a clear view of opportunity areas for decision-making. This chart is for illustrative purposes; the full report contains the complete analysis.
This chart highlights the Total Addressable Market (TAM) by estimating the maximum revenue opportunity using an assumption-driven approach, supporting strategic planning and opportunity sizing across markets. The chart is illustrative; the full report provides a more comprehensive analysis.
Access full TAM calculations and growth projections in our report Get Report
What Key Data and Analysis Are Included in the Gastrointestinal Stromal Tumor Market Report 2026?
The gastrointestinal stromal tumor market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the gastrointestinal stromal tumor industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Gastrointestinal Stromal Tumor Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $1.46 billion |
| Revenue Forecast In 2030 | $1.98 billion |
| Growth Rate | CAGR of 8% from 2026 to 2030 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2030 |
| Segments Covered | Treatment Type, Indication, End-User |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain |
| Key Companies Profiled | Pfizer Inc., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Merck & Co. Inc., GlaxoSmithKline plc, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca plc, Eli Lilly and Company, Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Jiangsu Hengrui Medicine Co. Ltd., Exelixis Inc., NATCO Pharma Ltd., Blueprint Medicines Corporation, Array BioPharma Inc., Deciphera Pharmaceuticals Inc., Ono Pharmaceutical Co. Ltd. |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |